Cardiac Bypass Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Coronary artery bypass grafting (CABG) is a major cardiac surgical procedure in which blood vessels harvested from elsewhere in the body — typically the internal mammary artery, radial artery, or saphenous vein from the leg — are used to create new conduits bypassing blocked or severely narrowed coronary arteries, restoring adequate blood supply to ischaemic heart muscle. It is one of the most commonly performed major operations in the world, with over 200,000 procedures performed annually in the United States alone, and remains the gold standard revascularisation strategy for patients with complex multi-vessel coronary artery disease.

The procedure is performed under general anaesthesia, typically lasting 3–6 hours. Conventional on-pump CABG uses a cardiopulmonary bypass machine (heart-lung machine) to oxygenate and circulate the blood while the surgeon operates on a motionless, stopped heart. Off-pump CABG (OPCAB) is performed on the beating heart using mechanical stabilisers to hold sections of the heart wall still, avoiding the systemic effects of cardiopulmonary bypass — relevant particularly in elderly patients, those with severe atherosclerosis of the aorta, or patients with significant comorbidities. The left internal mammary artery (LIMA) anastomosed to the left anterior descending artery (LAD) is the most durable conduit, with 10-year patency rates exceeding 90% and proven survival benefit over vein grafts alone.

The decision to offer CABG versus percutaneous coronary intervention (coronary stenting) is made by a Heart Team — a multidisciplinary group including an interventional cardiologist and cardiac surgeon — based on anatomical complexity of the coronary disease (SYNTAX score), left ventricular function, presence of diabetes, and patient preference. CABG consistently demonstrates superior long-term outcomes compared to PCI in patients with diabetes and multi-vessel disease, left main coronary artery stenosis, and complex three-vessel disease.

CABG is primarily indicated for obstructive coronary artery disease (CAD) causing myocardial ischaemia — reduced blood flow to heart muscle resulting in chest pain (angina), breathlessness, or silent ischaemia demonstrated on stress testing or imaging. The principal indications include significant left main coronary artery disease (stenosis greater than 50% of the left main stem), three-vessel coronary artery disease (particularly with reduced left ventricular ejection fraction or diabetes), two-vessel disease involving the proximal LAD with left ventricular dysfunction, and failed or incomplete coronary stenting.

CABG may also be performed in the acute setting following myocardial infarction where anatomy is not suitable for percutaneous revascularisation, or when mechanical complications of myocardial infarction (ventricular septal defect, mitral regurgitation from papillary muscle rupture) require concurrent surgical repair. Repeat CABG for failed prior grafts, CABG combined with aortic or mitral valve surgery, and CABG with surgical ventricular reconstruction for ischaemic cardiomyopathy are additional indications performed at specialist centres.

Ideal CABG candidates are patients with significant multi-vessel or left main coronary artery disease, adequate left ventricular function (ejection fraction greater than 35–40%) or impaired function where revascularisation is expected to improve cardiac performance, absence of absolute surgical contraindications, and physiological fitness to tolerate a major operation under general anaesthesia. Pre-operative cardiopulmonary fitness assessment using CPET guides risk stratification; patients with CPET oxygen uptake (VO2 max) below 14 mL/kg/min have significantly higher perioperative mortality.

Contraindications include severe non-cardiac comorbidities limiting life expectancy, no viable myocardium to revascularise (demonstrated by nuclear imaging or cardiac MRI), extremely poor ventricular function (ejection fraction below 20%) where benefit of revascularisation alone is uncertain, and absence of suitable conduit vessels. In patients deemed very high surgical risk, transcatheter aortic valve implantation (TAVI) approaches for combined valve and coronary disease, or hybrid procedures (robotic LIMA to LAD combined with PCI to other vessels), offer alternatives.

Conventional on-pump CABG using cardiopulmonary bypass is the most widely practiced technique, offering excellent exposure and the ability to perform technically precise, bloodless anastomoses. Off-pump CABG (OPCAB) avoids bypass and reduces the risk of cognitive dysfunction and aortic manipulation, with equivalent short-term outcomes in experienced hands; it is preferred for elderly patients, those with severe aortic atherosclerosis, or patients with renal impairment. Minimally invasive direct coronary artery bypass (MIDCAB) uses a small lateral thoracotomy incision to bypass the LAD with the LIMA without full sternotomy, offering reduced blood loss and faster recovery for single-vessel LAD disease.

Robotic CABG uses the da Vinci Surgical System to harvest the LIMA endoscopically and construct the anastomosis — or as part of a hybrid procedure combined with PCI. Bilateral internal mammary artery (BIMA) grafting using both internal mammary arteries provides superior long-term graft patency and survival benefit over single LIMA/saphenous vein combinations, and is particularly beneficial in younger patients, though it increases the risk of sternal wound complications in diabetic and obese patients. Total arterial revascularisation strategies — using LIMA, right internal mammary artery, and radial artery, avoiding vein grafts entirely — aim to maximise long-term graft durability. Total arterial revascularisation strategies, using combinations of bilateral internal mammary artery, right gastroepiploic artery, and radial artery, avoiding vein grafts entirely — aim to maximise long-term graft durability and reduce the need for re-intervention over decades. Enhanced recovery after cardiac surgery (ERAS) protocols incorporating early extubation, multimodal analgesia, and physiotherapy reduce ICU stay and hospital length of stay.

CABG consistently demonstrates superior long-term clinical outcomes versus medical therapy alone in appropriate candidates. Landmark trials — including COURAGE, BARI 2D, FREEDOM, and SYNTAX — establish CABG as the preferred revascularisation strategy for patients with three-vessel CAD, left main disease, and multi-vessel disease in diabetics. The FREEDOM trial demonstrated a significant reduction in mortality, myocardial infarction, and stroke at 5 years with CABG versus drug-eluting stenting specifically in diabetic patients with multi-vessel disease (18.7% vs 26.6% composite event rate).

Symptom relief from CABG is substantial: over 90% of patients experience complete elimination of angina at 1 year, compared to 72% with PCI. Improvements in exercise tolerance and quality of life are dramatic and durable. LIMA-to-LAD graft patency exceeds 90% at 10 years, while saphenous vein graft patency is 50–60% at 10 years — accounting for the long-term recurrence of symptoms and need for re-intervention in 20–30% of patients at 10 years. Left ventricular function improves in hibernating myocardium after successful revascularisation, with ejection fraction improvements of 5–15 percentage points observed in patients with ischaemic cardiomyopathy.

CABG carries an overall in-hospital mortality of approximately 1–3% at high-volume specialist cardiac surgery centres, rising to 5–8% in emergency settings or in patients with severely impaired ventricular function. The major perioperative complications include stroke (1–3%), perioperative myocardial infarction (approximately 5%), renal failure requiring temporary or permanent dialysis (1–3%), deep sternal wound infection (1–4%, higher in diabetic and obese patients), and pulmonary complications including atelectasis and pneumonia (10–20%).

Atrial fibrillation is the most common post-CABG arrhythmia, occurring in 20–40% of patients, typically on days 2–3, and usually self-terminating; it is managed with rate control, anticoagulation, and cardioversion if persistent. Cognitive dysfunction — subtle memory and concentration impairment — affects 20–40% of patients in the short term following cardiopulmonary bypass and is largely transient in most cases. Graft failure, whether early (technical anastomotic issues) or late (vein graft atherosclerosis), accounts for the recurrence of symptoms over time. Leg wound complications from saphenous vein harvest occur in approximately 5–10% of cases, including infection and lymphoedema.

Hospital stay after CABG is typically 5–7 days, with discharge to home when the patient is haemodynamically stable, pain is controlled on oral analgesia, and spirometry and ambulation targets are met. Mediastinal chest drains are removed within 24–48 hours; the sternal wound heals over 6–8 weeks and sternal wires remain permanently in place. Patients are advised to avoid lifting over 5 kg and driving for 6–8 weeks while the sternum heals. Most patients return to sedentary work within 6–8 weeks and physical work within 12–16 weeks.

Cardiac rehabilitation — a structured programme of supervised exercise, risk factor modification education, and psychological support — commences 4–6 weeks after surgery and is a class I guideline recommendation, demonstrating a 20–25% reduction in cardiovascular mortality. Mandatory medications after CABG include aspirin (or dual antiplatelet therapy), statins, beta-blockers, and ACE inhibitors in appropriate patients. Graft surveillance is typically with exercise stress testing or CT coronary angiography at 1–5 years in symptomatic patients.

CABG in the United States costs between $70,000 and $200,000 or more, depending on the complexity of surgery, hospital tier, and individual circumstances. Medicare covers CABG for eligible beneficiaries, but out-of-pocket costs remain significant. In the United Kingdom, NHS CABG is provided free at the point of care, though private surgery costs £20,000–£45,000.

India is the most popular medical tourism destination for cardiac bypass surgery, offering the procedure at internationally accredited hospitals (JCI or NABH certified) for approximately $5,000–$10,000 — a saving of 85–90% versus US costs. Leading Indian cardiac surgery centres including Fortis Escorts Heart Institute, Narayana Health, Apollo Hospitals, and Medanta — all with cardiac surgery volumes among the highest in the world — report outcomes fully comparable to Western centres. Thailand (Bumrungrad, Bangkok Heart Hospital) and Turkey (Acibadem) offer CABG for $10,000–$20,000. Poland and Hungary offer CABG within Europe for €10,000–€20,000. The volume-outcome relationship in cardiac surgery is particularly strong — selecting a high-volume centre (performing over 500 CABG procedures per year) is as important as cost considerations.

Percutaneous coronary intervention (PCI) with drug-eluting stents is the principal alternative to CABG for coronary revascularisation. PCI is preferred for single-vessel or simple two-vessel disease, and in patients who are poor surgical candidates due to comorbidities. CABG is superior to PCI for three-vessel disease, left main disease, and multi-vessel disease in diabetics in terms of long-term mortality and repeat revascularisation rates, as established in the SYNTAX, FREEDOM, and EXCEL trials.

Optimal medical therapy — intensive combination of antiplatelet agents, statins, ACE inhibitors, beta-blockers, and lifestyle modification — is appropriate for patients with stable angina who decline revascularisation or are poor candidates, though revascularisation is superior for symptom control and mortality in appropriate anatomical subsets. Transmyocardial laser revascularisation (TMR), a surgical procedure creating laser channels in ischaemic myocardium to stimulate angiogenesis, is occasionally used as an adjunct to CABG in areas where bypass conduits cannot be placed. Enhanced external counterpulsation (EECP) is a non-invasive angina treatment option for patients with refractory angina not suitable for revascularisation.